Mixed Dyslipidemia Clinical Trials

57 clinical trials for Mixed Dyslipidemia across international registries, including 9 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia — RECRUITING
• A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemia — RECRUITING
• Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days — RECRUITING · PHASE3
• A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib — RECRUITING
• A Study to Compare to PK Characteristics and Safety Profiles Between PA-111 and PA-111A — RECRUITING · PHASE1
• A Study to Evaluate the Efficacy and Safety of AD-218 — RECRUITING · PHASE3
• A DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED, MULTICENTER STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY ON LDL-C OF EVOLOCUMAB (AMG 145) IN SUBJECTS WITH HIV AND WITH HYPERLIPIDEMIA AND/OR MIXED DYSLIPIDEMIN — RECRUITING
• A 52 WEEK, PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPDEMIA OR MIXED DYSLIPIDEMIA AT RISK OF CARDIOVASCULAR EVENTS. SPIRE-LL: STUDIES OF PCSK9 INHIBITION AND THE REDUCTION OF VASCULAR EVENTS - LIPID LOWERING — RECRUITING · PHASE3
• "A MULTICENTER, CONTROLLED, OPEN-LABEL EXTENSION (OLE) STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF AMG 145." — RECRUITING
• A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events — NOT_YET_RECRUITING · PHASE3
• A Study to Evaluate the Effect of Food on the Pharmacokinetic Characteristics and Safety Profile of AD-117 in Healthy Adult Volunteers — COMPLETED · PHASE1
• A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia — COMPLETED · PHASE4
• A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients with Mixed Dyslipidemia — TERMINATED · PHASE2
• Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia — COMPLETED · PHASE2
• Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia — ACTIVE_NOT_RECRUITING
• Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of DW5421A/DW5421B Compared to Monotherapy of DW5421A — COMPLETED · PHASE3
• A Study to Assess the Real-World Effectiveness of Inclisiran and PCSK9 mAbs in Chinese Hypercholesterolemia Adult Patients — COMPLETED
• ATLANTIS Trial: Phospholipid Omega-3 Versus Conventional Omega-3 — NOT_YET_RECRUITING · NA
• Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD — ACTIVE_NOT_RECRUITING
• A Study in Patients With Mixed Dyslipidemia — ACTIVE_NOT_RECRUITING · PHASE2
• Clinical Trial to Evaluate the Safety, Pharmacokinetic Characteristics of DW5124 and DW5124-R, and the Effect of Food on DW5124 in Healthy Adult Volunteers — COMPLETED · PHASE1
• A Study to Compare to PK Characteristics and Safety Profiles Between AD-117 and AD-117A — NOT_YET_RECRUITING · PHASE1
• Study of ARO-ANG3 in Adults With Mixed Dyslipidemia — COMPLETED · PHASE2
• A Phase 2 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of ARO-APOC3 in Adults with Dyslipidemia — OTHER · PHASE2
• The Food Effect on PK Characteristics and Safety Profiles of PA-111 — NOT_YET_RECRUITING · PHASE1
• Study to Assess the Real World Effectiveness of Inclisiran in Chinese Adult Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia — COMPLETED
• Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133) — TERMINATED · PHASE3
• An Observational Study on the Identification of Prescription Patterns of STAFEN Cap — OTHER
• Treatment With Bempedoic Acid And/Or Its Fixed-dose Combination With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolemia Or Mixed Dyslipidemia — WITHDRAWN
• Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia — TERMINATED · PHASE3
• Bezafibrate Plus Berberine in Mixed Dyslipidemia — COMPLETED · PHASE3
• SurveY Followed by a Retrospective Chart Review to Describe the Key Factors Leading to Physician's Decision to Treat Patients at High and Very High Cardiovascular Risk With hyperchOlesterolemia or Mixed Dyslipidemia With NUSTENDI® — COMPLETED
• Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen — COMPLETED · PHASE3
• Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab — COMPLETED · PHASE1
• A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3561774 IN ADULTS WITH MIXED DYSLIPIDEMIA — COMPLETED · PHASE2
• A DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ARO-APOC3 IN ADULTS WITH MIXED DYSLIPIDEMIA — COMPLETED · PHASE2
• MK-0524B Lipid Study (MK-0524B-063) — COMPLETED · PHASE3
• Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143) — TERMINATED · PHASE3
• Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen — COMPLETED · PHASE3
• A Post-marketing Surveillance to Assess Safety and Efficacy of Rosuvatatin/Ezetimibe — OTHER
• Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia — COMPLETED · PHASE3
• Efficacy and Safety of Fluvastatin in Different Doses in Adults With Mixed Dyslipidemia or Primary Hypercholesterolemia — COMPLETED · PHASE3
• A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY OF EVOLOCUMAB (AMG 145) ON LDL-C IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND HYPERCHOLESTEROLEMIA/MIXED DYSLIPIDEMIA — COMPLETED
• Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119) — TERMINATED
• Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067) — COMPLETED · PHASE3
• A PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, LONG-TERM SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA AT RISK OF CARDIOVASCULAR EVENTS — COMPLETED · PHASE3
• Prevail-Us: A Study Of Pitavastatin 4 mg Vs. Pravastatin 40 mg In Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia — COMPLETED · PHASE4
• A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia — COMPLETED · PHASE3
• Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia — COMPLETED · PHASE3
• An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME) — COMPLETED · PHASE3

Refine this search